Soluble biomarkers of HIV transmission, disease progression and comorbidities

Current Opinion in HIV and AIDS

Volumn 8, Issue 2, 2013, Pages 117-124

  Leeansyah, Edwin ^a   Malone, David F G ^a   Anthony, Donald D ^b   Sandberg, Johan K ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

chemokines; cytokines; HIV; microbial translocation; soluble biomarkers

Indexed keywords

ACUTE PHASE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; CHEMOKINE; CYTOKINE; D DIMER; DEFENSIN; FATTY ACID BINDING PROTEIN; FIBRIN; FIBRINOGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYALURONIC ACID; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N(G),N(G) DIMETHYLARGININE; RANTES; RIBAVIRIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

BLOOD CLOTTING DISORDER; BREAST MILK; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE COURSE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MIXED INFECTION; MONOCYTE; MORTALITY; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BIOLOGICAL MARKERS; BODY FLUIDS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS;

EID: 84873481136     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835c7134     Document Type: Review

References (57)

1. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: Summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010; 5:480-490.
2. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5:498-503.
3. Bosire R, Guthrie BL, Lohman-Payne B, et al. Longitudinal comparison of chemokines in breastmilk early postpartum among HIV-1-infected and uninfected Kenyan women. Breastfeed Med 2007; 2:129-138.
4. Lohman-Payne B, Slyker JA, Moore S, et al. Breast milk cellular HIV-specific interferon gamma responses are associated with protection from peripartum HIV transmission. AIDS 2012; 26:2007-2016.
5. Farzin A, Ank B, Boyer P, et al. Amniotic fluid exhibits an innate inhibitory activity against HIV-1 replication in vitro. AIDS Res Hum Retroviruses 2012.
6. Dezzutti CS, Richardson BA, Marrazzo JM, et al. Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 Seroconversion in women participating in the HPTN 035 Trial. J Infect Dis 2012; 206:1931-1935.
7. Ghosh M, Fahey JV, Shen Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 2010; 5:e11366.
8. Mukura LR, Ghosh M, Fahey JV, et al. Genital tract viral load in HIV type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity. AIDS Res Hum Retroviruses 2012; 28:1533-1539.
9. Roberts L, Passmore JA, Mlisana K, et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis 2012; 205:194-203.
10. Naranbhai V, Abdool Karim SS, Altfeld M, et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012; 206:993-1001.
11. Anderson JA, Ping LH, Dibben O, et al. HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog 2010; 6:e1001053.
12. Kramer HB, Lavender KJ, Qin L, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 2010; 6:e1000893.
13. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-3733.
14. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: Timing of transmission, inflammation and antiretroviral therapy. PLoS One 2011; 6:e19617.
15. Jiao Y, Zhang T, Wang R, et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol 2012; 25:333-337.
16. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
17. Roberts L, Passmore JA, Williamson C, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010; 24: 819-831.
18. Katsikis PD, Mueller YM, Villinger F. The cytokine network of acute HIV infection: A promising target for vaccines and therapy to reduce viral setpoint? PLoS Pathog 2011; 7:e1002055.
19. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-484.
20. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4 T-cell changes independent of viral load. Blood 2004; 104:942-947.
21. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-666.
22. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2012.
23. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
24. Vassallo M, Mercie P, Cottalorda J, et al. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: A systematic literature review. Virol J 2012; 9:174.
25. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4 cell count. AIDS 2011; 25:1385-1394.
26. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA 2009; 106:6718-6723.
27. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
28. Raj DS, Shah VO, Rambod M, et al. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 2009; 54:1062-1071.
29. Eller MA, Blom KG, Gonzalez VD, et al. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS One 2011; 6:e18779.
30. Thiebaut R, Charpentier C, Damond F, et al. Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. Clin Infect Dis 2012; 55:1417-1425.
31. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-1230.
32. Marchetti G, Nasta P, Bai F, et al. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One 2012; 7:e32028.
33. Anthony DD, Conry SJ, Medvik K, et al. Baseline levels of soluble CD14 and CD1656- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis 2012; 206:969-973.
34. Shive CL, Biancotto A, Funderburg NT, et al. HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr 2012; 61:145-152.
35. Kramski M, Gaeguta AJ, Lichtfuss GF, et al. Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J Clin Microbiol 2011; 49: 3691-3693.
36. Kandanearatchi A, Brew BJ. The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders. FEBS J 2012; 279:1366-1374.
37. Crowe SM, Westhorpe CL, Mukhamedova N, et al. The macrophage: The intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87:589-598.
38. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
39. van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011; 24:273-278.
40. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
41. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
42. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-1646.
43. Peters L, Neuhaus J, Mocroft A, et al. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther 2011; 16:667-675.
44. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: A cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012; 17:1345-1349.
45. Eastburn A, Scherzer R, Zolopa AR, et al. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One 2011; 6:e26320.
46. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
47. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med 2011; 7:e1000384.
48. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-1567.
49. Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57:371-379.
50. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 2012; 60:234-243.
51. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154-163.
52. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
53. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
54. Pandrea I, Cornell E, Wilson C, et al. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012; 120: 1357-1366.
55. Jang JJ, Berkheimer SB, Merchant M, Krishnaswami A. Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis 2011; 217:514-517.
56. Baker JV, Neuhaus J, Duprez D, et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012; 60:128-134.
57. Cocchi F, DeVico AL, Lu W, et al. Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of beta chemokines and RNases. Proc Natl Acad Sci USA 2012; 109:5411-5416.